Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Type:
Grant
Filed:
March 4, 2020
Date of Patent:
January 31, 2023
Assignees:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Abstract: This disclosure provides a novel label-free N-glycan analysis method to detect and quantify N-glycans and N-linked glycosylation profiles without using a label, such as a fluorescent label. This method allows for reduced sample preparation and chromatographic separation times, and can be used for product batch release.
Type:
Application
Filed:
November 23, 2020
Publication date:
January 26, 2023
Applicant:
Bristol-Myers Squibb Company
Inventors:
Letha CHEMMALIL, Julia DING, Zhengjian LI
Abstract: The present invention provides compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds, including compounds of Formula (I) or prodrugs thereof; optionally in combination with an additional cancer therapeutic agent, and methods of use thereof for treating proliferative diseases and disorders such as Desmoid tumors.
Type:
Application
Filed:
September 12, 2022
Publication date:
January 19, 2023
Applicants:
Bristol-Myers Squibb Company, Ayala Pharmaceuticals Inc.
Inventors:
Bruce S. FISCHER, Gaurav Bajaj, Matti Davis, Joel Kaye
Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
Type:
Grant
Filed:
July 31, 2019
Date of Patent:
January 17, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Yam B. Poudel, Sanjeev Gangwar, Liqi He, Prasanna Sivaprakasam, Matthias Broekema, Matthew Cox, Christine M. Tarby, Qian Zhang, Naidu S. Chowdari
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR6R6 or C?O; Ring A is: and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
Type:
Grant
Filed:
November 18, 2020
Date of Patent:
January 10, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Andrew P. Degnan, Godwin Kwame Kumi, Audris Huang, James Aaron Balog, Ashok Vinayak Purandare, Weifang Shan, Guo Li
Abstract: In certain embodiments, the disclosure provides an IgG4 antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises: (a) a modified IgG4 CH1 region having a substitution of the lysine residue at position 196; or (b) a modified IgG4 hinge region having a substitution of the serine residue at position 217, the glycine residue at position 220, the proline residue at position 224 or the proline residue at position 225. Preferably, the IgG4 antibody further comprises a substitution of the serine residue at position 228 in the heavy chain hinge region.
Abstract: The disclosure provides a method of treating unresectable or metastatic melanoma in a human patient with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method includes a combination of the LAG-3 antagonist with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor. In some aspects, the method includes one or more additional therapeutic agents and/or anti-cancer therapies.
Abstract: Disclosed herein are nucleic acid molecules, polypeptides, cells, vectors, and pharmaceutical compositions relating to miniaturized dystrophin. Methods of production and methods of therapeutic use of the miniaturized dystrophin are also disclosed.
Type:
Grant
Filed:
April 28, 2021
Date of Patent:
December 27, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
Glen Banks, Jonathan Harry Davis, Paul Charles Levesque
Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer.
Type:
Grant
Filed:
October 14, 2019
Date of Patent:
December 20, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
John J. Engelhardt, Mark J. Selby, Alan J. Korman, Mary Diane Feingersh, Brenda L. Stevens
Abstract: The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
Type:
Grant
Filed:
June 11, 2020
Date of Patent:
December 20, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
Nicholas R. Wurtz, Pravin Sudhakar Shirude
Abstract: In accordance with the present invention, CHO cells expressing a recombinant polypeptide of interest are grown in media where the amino acids, vitamins, phosphate, lipids and/or antioxidant optimization is utilized to manipulate and/or control the protein quality attributes of the polypeptides. Polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.
Abstract: The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein.
Type:
Grant
Filed:
August 7, 2019
Date of Patent:
December 13, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
Anurag S. Srivastava, Robert J. Cherney, Khehyong Ngu
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
Type:
Grant
Filed:
January 24, 2020
Date of Patent:
December 13, 2022
Assignee:
Bristol-Myers Squibb Company
Inventors:
Dasa Lipovsek, Joseph Toth, Ginger C. Rakestraw, Irvith M. Carvajal, Stanley Richard Krystek, Jr., Steven R. O'Neil, Guodong Chen, Richard Y. Huang, Bryan C. Barnhart, John Thomas Loffredo, Christina Terragni
Abstract: This disclosure provides a method for treating a subject afflicted with a renal cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent may be an anti-angiogenic tyrosine kinase inhibitor or an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody. The disclosure also provides a kit for treating a subject afflicted with a renal cancer, the kit comprising a dosage of an anti-PD-1 antibody, a dosage of another anti-cancer agent which is an anti-angiogenic tyrosine kinase inhibitor or an anti-CTLA-4 antibody, and instructions for using the anti-PD-1 antibody and the other anti-cancer agent in any of the disclosed methods for treating a renal cancer.
Type:
Application
Filed:
May 4, 2022
Publication date:
December 8, 2022
Applicant:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Maria JURE-KUNKEL, Paul GAGNIER, David FELTQUATE
Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
Type:
Application
Filed:
July 28, 2022
Publication date:
December 8, 2022
Applicants:
Pfizer Inc., Bristol-Myers Squibb Company
Inventors:
Robert ARCH, Jun ZHANG, Michelle MADER, Tetsuya ISHINO, Joel BARD, William FINLAY, Orla CUNNINGHAM, Ciara REILLY, Peter BRAMS, Brigitte DEVAUX, Haichun HUANG, Karla HENNING
Abstract: The disclosure provides methods for measuring M-proteins in a biological sample obtained from a subject, comprising applying purified immunoglobulins to a liquid chromatography (LC) mass spectrometry (MS). In some aspects, the immunoglobulins are purified using an immunocapture (IC). In certain aspects, the subject has a plasma cell disorder, e.g., multiple myeloma.
Type:
Application
Filed:
November 4, 2020
Publication date:
December 8, 2022
Applicant:
Bristol-Myers Squibb Company
Inventors:
Rasa SANTOCKYTE, Jianing ZENG, Oscar PUIG
Abstract: The invention relates to water soluble 18F-prosthetic groups and the synthesis and use of 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression are disclosed.
Abstract: Provided herein are polypeptides comprising a modified fibronectin type III (Fn3) domain, wherein the amino acid corresponding to residue 58 of SEQ ID NO: 1 is mutated, and wherein the solubility is enhanced relative to the solubility of a Fn3 domain in which the amino acid corresponding to residue 58 of SEQ ID NO: 1 is not mutated. Also provided are libraries comprising a plurality of the polypeptides and a method for identifying a polypeptide that binds to a target.
Abstract: The present disclosure provides methods of identifying a subject suitable for an immunooncology (I-O) therapy comprising measuring the expression of one or more genes of a pantumor inflammation gene panel. In some aspects, the method further comprises administering an I-O therapy to the subject. In some aspects, the I-O therapy comprises administering an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof to the subject.
Type:
Application
Filed:
May 29, 2020
Publication date:
November 17, 2022
Applicant:
Bristol-Myers Squibb Company
Inventors:
Peter M. SZABO, Lan ZHANG, Keyur H. DESAI, Neeraj ADYA, Zhenhao QI, Kim ZERBA, Scott Adams ELY, Saumya PANT, George A. GREEN
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
Type:
Grant
Filed:
September 3, 2020
Date of Patent:
January 3, 2023
Assignee:
Bristol-Myers Squibb Company
Inventors:
Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Badu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf